#Teva is an active hashtag on Bluesky. In the last 30 days, 10 people shared 39 posts with it — around 1 a day. Activity is up 71% versus the previous week, peaking on Oct 13 with 6 posts.
www.irishexaminer.com
Irish hospital consultants vote to boycott products made by Israeli pharma company
Motion said position was being taken as Teva Pharmaceuticals faces 'significant ethical concern and international scrutiny in the context of the ongoing conflict' in Gaza
www.amazon.co.jp
レディース VOYA INFINITYサンダル
Teva / 実質 2,614円
www.amazon.co.jp
レディース HYDRATREK SANDALスポーツサンダル
Teva / 実質 5,023円
www.amazon.co.jp
レディース HYDRATREK SANDALスポーツサンダル
Teva / 実質 5,023円
www.amazon.co.jp
レディース MIDFORM UNIVERSALサンダル
Teva / 実質 4,311円
statnews.com
Pharmalittle: We're reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more
The FDA gave tentative approval to Dr. Reddy’s Laboratories to make a generic version of a groundbreaking HIV prevention medicine
www.stocktitan.net
Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva (TEVA) signed an agreement with Samsung Bioepis for U.S. commercialization rights to two FDA-approved biosimilars for inflammatory and autoimmune conditions. Biosimilars are biological medicines referencing existing biologic treatments. The products are ETICOVO (etanercept-ykro), referencing Enbrel, and infliximab-abda, referencing Remicade.ETICOVO rights transfer at closing; infliximab-abda rights transfer in Q3 2027. The transaction is anticipated to close by the end of 2026, subject to necessary regulatory approvals and customary closing conditions. ETICOVO is not currently available in the U.S.; its commercialization timing will be announced later. Samsung Bioepis retains manufacturing and regulatory oversight. Subject to certain conditions, Teva will make an upfront payment over the next 3 years, with possible additional launch and sales milestone payments. The companies will share commercialization profits.
www.amazon.co.jp
レディース VOYA INFINITYサンダル
Teva / 実質 2,614円
www.amazon.co.jp
レディース HYDRATREK SANDALスポーツサンダル
Teva / 実質 5,023円
www.irishexaminer.com
Irish hospital consultants vote to boycott products made by Israeli pharma company
Motion said position was being taken as Teva Pharmaceuticals faces 'significant ethical concern and international scrutiny in the context of the ongoing conflict' in Gaza
www.amazon.co.jp
レディース HYDRATREK SANDALスポーツサンダル
Teva / 実質 5,023円
www.amazon.co.jp
レディース MIDFORM UNIVERSALサンダル
Teva / 実質 4,311円
statnews.com
Pharmalittle: We're reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more
The FDA gave tentative approval to Dr. Reddy’s Laboratories to make a generic version of a groundbreaking HIV prevention medicine
www.stocktitan.net
Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva (TEVA) signed an agreement with Samsung Bioepis for U.S. commercialization rights to two FDA-approved biosimilars for inflammatory and autoimmune conditions. Biosimilars are biological medicines referencing existing biologic treatments. The products are ETICOVO (etanercept-ykro), referencing Enbrel, and infliximab-abda, referencing Remicade.ETICOVO rights transfer at closing; infliximab-abda rights transfer in Q3 2027. The transaction is anticipated to close by the end of 2026, subject to necessary regulatory approvals and customary closing conditions. ETICOVO is not currently available in the U.S.; its commercialization timing will be announced later. Samsung Bioepis retains manufacturing and regulatory oversight. Subject to certain conditions, Teva will make an upfront payment over the next 3 years, with possible additional launch and sales milestone payments. The companies will share commercialization profits.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
